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Introduction
Blau Syndrome (Blau) is a granulomatous auto-inflamma-
tory disease caused by mutations in NOD2 that have been
proposed to result in phosphorylation of RIP2 kinase and
the production of pro-inflammatory cytokines. Such
monogenic diseases can bring to light pathways that are
also likely to be involved in more genetically complex
diseases. For example, increased RIP2 phosphorylation has
been observed in inflammatory bowel disease (IBD),
although the role of RIP2 in IBD has not been determined.
We are developing a first-in-class, highly potent and
selective inhibitor of RIP2 kinase, which may provide ther-
apeutic benefit in both Blau and IBD.
Objectives
To explore the role of RIP2 in disease, we examined its
phosphorylation state in peripheral blood mononuclear
cells (PBMCs) and synovial fluid (SF) cells isolated from
a cohort of Blau patients. We also assessed the ability of
a RIP2 inhibitor to block inflammatory cytokine produc-
tion in ex vivo-cultured mucosal biopsies from IBD
patients.
Methods
Phospho-Serine176-RIP2 (pRIP2) levels were measured in
PBMCs from 5 Blau patients and 4 normal healthy volun-
teers (NHVs) and SF cells from the inflamed knee joints of
1 Blau patient by immunoblotting with a novel monoclo-
nal antibody. Inflamed biopsies from 28 IBD patients were
cultured ex vivo in serum-free media for 18 hrs in the
presence or absence of RIP2 inhibitor GSK’214, and
culture supernatants were assayed for TNF-a, IL-1b and
IL-6 by ELISA.
Results
pRIP2 levels were found to be elevated by an average of
8-fold in PBMCs isolated from Blau patients relative to
NHVs. SF cells from a Blau patient also expressed 240-
fold higher levels of pRIP2 than NHV PBMCs. Studies
are underway to assess the effect of RIP2 inhibition on
pRIP2 in cultured PBMCs from Blau patients.
Treatment with RIP2 inhibitor GSK’214 resulted in
dose-dependent inhibition of pRIP2 in ex vivo-cultured
IBD biopsies. GSK’214 also inhibited spontaneous produc-
tion of TNF-a, IL-1b and IL-6 in these cultures, with
efficacy equivalent to that of prednisolone or dexametha-
sone. Similar results were observed with biopsies from
both Crohn’s disease and ulcerative colitis patients.
Conclusion
Studies in transfected cells have suggested that Blau
NOD2 mutations act in a gain-of-function manner, how-
ever, direct evidence for the activation of RIP2 in patients
has been lacking. We have for the first time shown that
increased phosphorylation of RIP2 on Serine176, a well-
established phosphorylation site associated with kinase
activation, occurs in primary Blau patient cells, confirming
the dominant gain-of-function nature of these mutations.
Prompted by reports of increased pRIP2 in mucosal tissues
from IBD patients, we have also shown that inhibition of
RIP2 activation suppresses the spontaneous production of
inflammatory cytokines by ex vivo-cultured IBD biopsies.
Our results suggest that both Blau and IBD patients may
benefit from therapeutic inhibition of RIP2.
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